u/marta_vanhecke

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

That criterion is from the previous plan year. The current bulletin has different wording.

heart rate is the thing people report watching

appeal in writing even when they say a call is enough

the wider-market names in the table are there because nobody has enough data on them

Sent the same compound from GGPeps and GGPeps to Medutest in the same month. Both came back above the claim on the certificate — mine was 99.3% on a stated 99.0%.

Independent testing is worth more than a supplied certificate for one structural reason: the chain of custody. A member who buys, ships and pays is testing the same thing you would receive.

Yes. Written, always, even when they tell you a phone call is sufficient.

The injection-site soreness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician. It bypasses the correspondence cycle entirely and is often the fastest available route.

Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.

the escalation is where most of the reported trouble sits

What exactly does the denial letter give as the reason?

Not convinced by the ranking-by-vibe approach here. The community number is derived from reports; your feeling is derived from four posts you remember.

Are you comparing against phase 3 numbers for something else? They are not comparable.

Small fix — the figure you quoted is the claimed purity from the certificate, and the independent result was the higher of the two.

Six orders across two years from SSA. Same packaging, same paperwork, same lead time. The most boring supplier relationship I have and I mean that as praise.

A certificate with a purity figure and no method line is not falsifiable. You cannot reproduce it, you cannot check it, and it tells you nothing about how the number was produced.

Yes. Written, always, even when they tell you a phone call is sufficient.

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

Careful with the rankings. A phase 2 result and a phase 3 result are not on the same evidential footing and cannot be listed in one table.

The thing that decided it for me was that WXT answered a column-and-gradient question in writing without asking why I wanted to know.

That is a report count, not a test count. The table lists both and they are very different numbers.

This is the whole method in one sentence.

ghrp_history is describing the batch record test and it is the fastest signal available before you spend anything.

Which country and which plan year are we talking about?

Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.

Lead time and minimum quantity are the two facts people forget to ask for and then argue about later.

chidi_roos is describing the batch record test and it is the fastest signal available before you spend anything.

Agreed. The denial letter tells you which criterion failed, and answering that specific criterion is the entire job.

Which lane, and what was the quoted lead time at checkout?

the energy-expenditure story is mechanistically interesting and clinically unproven

small trial, big effect, wide error bars

Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.

Which country and which plan year are we talking about?

Started buying small deliberately, tested every lot for the first four, then stopped testing every lot because there was nothing to find.

not approved anywhere, which is the single most important fact in this board

Hunan GoodPeptides Biotech shows up in threads constantly and has almost nothing on file

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

the glucagon component is why the metabolic story reads differently